Supplemental Table S1. Baseline Clinical Characteristics and Previous Uses of Anti-Osteoporotics in Total Eligible Injections ($n=218,823$)

Characteristic	Injections
Age, yr	69.5±9.0
No. of denosumab injections	2.5±0.8
Min-max	2–7
Duration of treatment, day	484.4±170.4
Min-max	330–1,355
Previous history of all fracture	81,802 (37.4)
Previous history of vertebral fracture	53,398 (24.4)
Previous use of anti-osteoporotic[a]	
SERMs	13,310 (6.1)
BPPs	76,818 (35.1)
Teriparatide	1,383 (0.6)
None	127,312 (58.2)

Values are expressed as mean±standard deviation or number (%) unless otherwise indicated.

SERM, selective estrogen receptor modulator; BPP, bisphosphonate.

[a]Usages of anti-osteoporoptics within the 1 year from the initiating denosumab.